02219nas a2200253 4500000000100000008004100001260004300042653003400085653003200119100002600151700002300177700001200200700002100212700001900233700001900252700002900271700001900300245006000319856005700379300001200436490000600448520149700454022001401951 2019 d bPeertechz Publications Private Limited10aMu-opioid receptor expression10aMultibacillary leprosy (MB)1 aPatrícia Elizabeth P1 aLeonardo Pereira Q1 aHelen F1 aAdelaide Lopes A1 aRoberta Olmo P1 aLuiz Claudio F1 aFrancisco das Chagas DCR1 aMaria Inês FP00aMu-opioid receptor expression in multibacillary leprosy uhttps://www.clinsurggroup.us/articles/OJTM-3-110.pdf a014-0190 v33 a
Background: During the clinical course of multibacillary leprosy disease, mainly in Lepromatous Leprosy (LL) patients, acute and systemic infl ammatory episodes known as Erythema Nodosum Leprosum (ENL) may be present. The histology of ENL skin lesions initially shows hyperplasia of epidermis followed by a neutrophilic infl ammatory process. Sensory neurons and keratinocyte communicate in paracrine way via molecules such as neuropeptides, cytokines, and opioids. Previous studies demonstrated that opioids might cause immunosuppression through Mu Opioid Receptor (MOR).
Objectives: To verify the expression of MOR in leprosy multibacillary patients with and without ENL.
Methods: Cutaneous lesions from fi fteen patients with LL with no reaction and 18 patients with ENL from Oswaldo Cruz Foundation, Brazil, were studied. Immunohistochemistry reaction with anti-MOR antibody was performed in paraffi n embedded skin lesions biopsy.
Results: Forty-six percent of LL patients without reactional episodes presented positivity for MOR in keratinocytes while in the ENL group 88.9% presented strong staining in epidermis (p=0.02), In lepromatous lesions, almost all macrophages were positive for MOR, in contrast to the rare positivity in ENL macrophages.
Main Conclusions: The data presented here suggest the involvement of MOR in the immunomodulation of ENL
a2640-8147